As an example, Saei and collaborators developed a comprehensive chemical proteomics profiling approach for target deconvolution of a redox active drug auranofin (originally and anti-rheumatic called Ridaura) as an anti-cancer drug auranofin was found to target genes such as TXNRD1, NFKB2, and CHORDC1, all of them known to be involved in the perturbation of oxidoreductase pathways in cancer (181). The gene discussed is NFKB2; the disease is cancer.